Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Sep;34 Suppl 1(Suppl1):57-59.
doi: 10.37201/req/s01.17.2021. Epub 2021 Sep 30.

Antiviral therapy and immunotherapy of COVID-19

C Crespillo, S Moreno  1
Affiliations
Review

Antiviral therapy and immunotherapy of COVID-19

C Crespillo et al. Rev Esp Quimioter. 2021 Sep.

Abstract

The pharmacological treatment of COVID-19 has evolved in the months since the description of the disease. Published observational studies and, above all, clinical trials have highlighted drugs that are useful as well as ruled out any benefit from other drugs used at the beginning of the pandemic. The pathogenesis of the disease has suggested that patients may benefit from the administration of both antivirals, mainly in the earliest stages, and anti-inflammatory/immunomodulatory medications in more advanced stages. We present a short review of the drugs used and under investigation for the treatment of COVID-19.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interests.

Figures

Figure 1
Figure 1
Evolution of COVID-19 and proposal of staging [adapted from Siddiqi et al. (1)]
See this image and copyright information in PMC

References

    1. Siddiqi HK, Mehra MR. COVID-19 illness in native and immuno-suppressed states: A clinical-therapeutic staging proposal. J Heart Lung Transplant. 2020; 39: 405-407. - PMC - PubMed
    1. Beigel JH, Tomashek KM, Dodd LEet al. . Remdesivir for the Treatment of Covid-19-Final Report. N Engl J Med 2020; 383: 1813-26. - PMC - PubMed
    1. Grein J, Ohmagari N, Shin Det al. . Compassionate Use of Remdesivir for Patients with Severe Covid-19. N Engl J Med 2020; 382: 2327-36. - PMC - PubMed
    1. Olender SA, Perez KK, Go ASet al. . Remdesivir for Severe COVID-19 versus a Cohort Receiving Standard of Care. Clin Infect Dis 2020. - PMC - PubMed
    1. Consortium WHOST, Pan H, Peto Ret al. . Repurposed Antiviral Drugs for Covid-19-Interim WHO Solidarity Trial Results. N Engl J Med 2021; 384: 497-511. - PMC - PubMed

Substances